The Global Health Body Raises Concern Over Acute Scarcity of Obesity Medications

Less than one in 10 individuals who could benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it releases its inaugural guidance on the therapies.

With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for more widespread and fairer availability to these injectable treatments.

Per estimates, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"Our latest guidelines recognises that obesity is a lifelong illness that can be addressed with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, constrained manufacturing, and distribution challenges are major hurdles to broad availability to the jabs that can help people shift considerable weight, notes the agency.

GLP-1 Therapy Shortage

Despite the present best projected outlook, the production of such drugs would only suffice for around 100 million people – under 10% of the global need, per the health organization.

The advice urges countries and companies to widen availability, through strategies like licensing agreements.

Exclusive production rights on a key compound – the primary ingredient of a leading brand – is set to lapse in several countries in 2026.

The Way Obesity Drugs Operate

These medications replicate a body's own hormone to slow digestion, curb appetite and boost feelings of fullness so users eat less.

Individuals commonly see weight reduction after several weeks of starting on the weekly injections.

Research points to people may regain a significant portion after a year of discontinuing the drug, when their normal appetite come back.

To be overweight or obese elevates your risk for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and some malignancies.

Excess weight impacts individuals in every country and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.